Retatrutide, from Soma Chems , is gaining increasing attention as a potential method for obesity control . This dual-action drug combines the properties of a GLP-1 receptor activator and a GIP receptor stimulant, aiming to not only promote weight loss but also improve underlying metabolic factors. Early patient trials have shown encouraging results